statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the Best Overall...

Castle Biosciences IDgenetix Test Receives 2024 MedTech Breakthrough Award for Best Overall Mental Health Solution

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a study further confirming the performance of its...

Largest Prospective Study to Date Further Supports Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test...

DecisionDx-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2024...

Castle Biosciences Reports First Quarter 2024 Results

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives...

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswoods Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter...

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing...

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial officer...

Castle Biosciences Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,368 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price...

Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $51,385.60 in Stock

Investors considering a purchase of Castle Biosciences Inc (CSTL) shares, but tentative about paying the going market price of 20.86/share, might benefit from considering selling puts among the...

Commit To Buy Castle Biosciences At $15, Earn 11.8% Annualized Using Options

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Watchers	938
52-Wk Low	$9.26
52-Wk High	$26.70

Volume	357,764.00
52-Wk High	$26.70
52-Wk Low	$9.26

CSTL Castle Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals